LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for neuropsychiatric diseases, with a particular emphasis on conditions such as schizophrenia and bipolar depression. The company’s primary focus lies in advancing its lead product candidate, LB-102, a chemically modified derivative of amisulpride—an established second-generation antipsychotic. LB-102 is designed to offer an improved therapeutic profile, aspiring to become the first benzamide antipsychotic approved for neuropsychiatric disorders in the United States. LB Pharmaceuticals builds its strategy on the extensive clinical experience with amisulpride and positive phase 2 clinical data for LB-102 in acute schizophrenia, aiming for further clinical development in both schizophrenia and bipolar depression. The company’s pipeline underscores its commitment to addressing unmet needs in mental health through innovative treatments. Founded in 2015 and headquartered in New York, LB Pharmaceuticals plays a notable role in the healthcare and biotechnology sectors by targeting disorders with significant societal impact and striving to set new standards in psychiatric care.